KOBO Biotech (531541.BO) Stock Price

KOBO Biotech Price

CLOSED
4.10
​
Market closed

Revenue at KOBO Biotech has contracted by 9.2% per year over the past 9 years to 325.40 M INR. Earnings per share have grown at 25.8% per year over the last 4 years. For KOBO Biotech, the net margin of -50.6% is down versus 5.3% a few years ago. At today's price the dividend yield works out to roughly 24.39%. The payout ratio is around 21% of earnings.

KOBO Biotech stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KOBO Biotech business model & stock analysis

Kobo Biotech Ltd. focuses on manufacturing active pharmaceutical ingredients (APIs)/bulk drugs. The company operates within the pharmaceuticals sector, producing bulk drugs for the industry. Its primary market segment consists of pharmaceutical manufacturers seeking reliable API suppliers. The firm's Solapur site in India is currently inactive, with no operational activities ongoing there. The company's revenue streams derive from the sale of manufactured APIs and bulk drugs to pharmaceutical companies. These products are essential components in the production of finished pharmaceutical formulations. Kobo Biotech Ltd. serves as a key supplier within the pharmaceutical supply chain, providing critical raw materials to its clients. The business model centers on bulk drug manufacturing, with the company acting as a supplier to other pharmaceutical firms. There are no additional product lines or services mentioned beyond API and bulk drug production. The firm's focus remains strictly on the manufacturing of active pharmaceutical ingredients and bulk drugs for the pharmaceutical industry.

Frequently asked questions about KOBO Biotech

Converted at the current exchange rate, the KOBO Biotech share trades at 0.04 EUR (4.10 INR).

The revenue cannot currently be calculated for KOBO Biotech.

The profit cannot currently be calculated for KOBO Biotech.

The P/E ratio cannot be calculated for KOBO Biotech at the moment.

The P/S cannot be calculated for KOBO Biotech currently.

The Eulerpool Quality Score for KOBO Biotech is 2/10.

The ISIN of KOBO Biotech is INE881A01015. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of KOBO Biotech is 531541.BO. The ticker symbol is used to trade KOBO Biotech shares on the stock exchange.

Fair ValueTerminal
3.98 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Jan 8, 1996
ISIN
INE881A01015
Cusip
Y0486K119
Market capitalization
97.66 M INRMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.52
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-72.69 %
Dividend
Dividend yield
0.00 %
Payout Ratio
19.27 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
20.00 %
Last updated Oct 28, 2026, 7:57 AM

KOBO Biotech Peer Group

KOBO Biotech FIGI

KOBO:IN · BBG000GFJNQ9KOBO:IB · BBG000GFKQJ8

All fundamentals and in-depth analysis of KOBO Biotech

Our stock analysis for KOBO Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of KOBO Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.